169 related articles for article (PubMed ID: 33121232)
1. Pituitary iron and factors predictive of fertility status in transfusion dependent thalassemia.
Singer ST; Fischer R; Allen I; Lal A; Vichinsky E; Yuan Q; Wang ZJ
Haematologica; 2021 Jun; 106(6):1740-1744. PubMed ID: 33121232
[TBL] [Abstract][Full Text] [Related]
2. Iron overload in transfusion-dependent thalassemia.
Saliba A; Taher A
Hematology; 2015 Jun; 20(5):311-2. PubMed ID: 25967377
[No Abstract] [Full Text] [Related]
3. Iron Chelation Therapy as a Modality of Management.
Aydinok Y
Hematol Oncol Clin North Am; 2018 Apr; 32(2):261-275. PubMed ID: 29458731
[TBL] [Abstract][Full Text] [Related]
4. MRI for Iron Overload in Thalassemia.
Fernandes JL
Hematol Oncol Clin North Am; 2018 Apr; 32(2):277-295. PubMed ID: 29458732
[TBL] [Abstract][Full Text] [Related]
5. Fertility and Pregnancy in Women with Transfusion-Dependent Thalassemia.
Carlberg KT; Singer ST; Vichinsky EP
Hematol Oncol Clin North Am; 2018 Apr; 32(2):297-315. PubMed ID: 29458733
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of Iron Overload Between Age Groups Using Magnetic Resonance Imaging and Its Correlation with Iron Profile in Transfusion-dependent Thalassemia.
Wahidiyat PA; Iskandar SD; Sekarsari D
Acta Med Indones; 2018 Jul; 50(3):230-236. PubMed ID: 30333273
[TBL] [Abstract][Full Text] [Related]
7. Deferasirox for the treatment of iron overload in non-transfusion-dependent thalassemia.
Taher AT; Temraz S; Cappellini MD
Expert Rev Hematol; 2013 Oct; 6(5):495-509. PubMed ID: 24083402
[TBL] [Abstract][Full Text] [Related]
8. Iron chelation therapy for non-transfusion-dependent thalassemia (NTDT): a status quo.
Taher AT; Musallam KM; Viprakasit V; Porter JB; Cappellini MD
Blood Cells Mol Dis; 2014; 52(2-3):88-90. PubMed ID: 24041597
[No Abstract] [Full Text] [Related]
9. Iron overload in thalassemia: different organs at different rates.
Taher AT; Saliba AN
Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):265-271. PubMed ID: 29222265
[TBL] [Abstract][Full Text] [Related]
10. Fertility in transfusion-dependent thalassemia men: effects of iron burden on the reproductive axis.
Singer ST; Killilea D; Suh JH; Wang ZJ; Yuan Q; Ivani K; Evans P; Vichinsky E; Fischer R; Smith JF
Am J Hematol; 2015 Sep; 90(9):E190-2. PubMed ID: 26044409
[No Abstract] [Full Text] [Related]
11. Interaction of Transfusion and Iron Chelation in Thalassemias.
Porter JB; Garbowski MW
Hematol Oncol Clin North Am; 2018 Apr; 32(2):247-259. PubMed ID: 29458730
[TBL] [Abstract][Full Text] [Related]
12. Profile of deferasirox for the treatment of patients with non-transfusion-dependent thalassemia syndromes.
Ricchi P; Marsella M
Drug Des Devel Ther; 2015; 9():6475-82. PubMed ID: 26719673
[TBL] [Abstract][Full Text] [Related]
13. Assessment and treatment of cardiac iron overload in thalassemia.
Aessopos A; Farmakis D; Andreopoulos A; Tsironi M
Hemoglobin; 2009; 33 Suppl 1():S87-92. PubMed ID: 20001638
[TBL] [Abstract][Full Text] [Related]
14. Iron overload in thalassemia and sickle cell disease.
Taher A
Semin Hematol; 2005 Apr; 42(2 Suppl 1):S5-9. PubMed ID: 15846583
[No Abstract] [Full Text] [Related]
15. Quantification of liver iron overload by T2 quantitative magnetic resonance imaging in thalassemia: impact of chronic hepatitis C on measurements.
Papakonstantinou O; Kostaridou S; Maris T; Gouliamos A; Premetis E; Kouloulias V; Nakopoulou L; Kattamis C
J Pediatr Hematol Oncol; 1999; 21(2):142-8. PubMed ID: 10206461
[TBL] [Abstract][Full Text] [Related]
16. Iron Overload and Chelation Therapy in Non-Transfusion Dependent Thalassemia.
Bou-Fakhredin R; Bazarbachi AH; Chaya B; Sleiman J; Cappellini MD; Taher AT
Int J Mol Sci; 2017 Dec; 18(12):. PubMed ID: 29261151
[TBL] [Abstract][Full Text] [Related]
17. Iron overload in non-transfusion-dependent thalassemia: association with genotype and clinical risk factors.
Tantiworawit A; Charoenkwan P; Hantrakool S; Choeyprasert W; Sivasomboon C; Sanguansermsri T
Int J Hematol; 2016 Jun; 103(6):643-8. PubMed ID: 27052211
[TBL] [Abstract][Full Text] [Related]
18. Daily alternating deferasirox and deferiprone therapy successfully controls iron accumulation in untreatable transfusion-dependent thalassemia patients.
Pinto VM; Balocco M; Quintino S; Bacigalupo L; Gianesin B; Rizzi M; Malagò R; De Franceschi L; Forni GL
Am J Hematol; 2018 Oct; 93(10):E338-E340. PubMed ID: 30033633
[No Abstract] [Full Text] [Related]
19. Heart Rate Variability as an Alternative Indicator for Identifying Cardiac Iron Status in Non-Transfusion Dependent Thalassemia Patients.
Wijarnpreecha K; Siri-Angkul N; Shinlapawittayatorn K; Charoenkwan P; Silvilairat S; Siwasomboon C; Visarutratna P; Srichairatanakool S; Tantiworawit A; Phrommintikul A; Chattipakorn SC; Chattipakorn N
PLoS One; 2015; 10(6):e0130837. PubMed ID: 26083259
[TBL] [Abstract][Full Text] [Related]
20. Adrenal insufficiency: An emerging challenge in thalassemia?
Baldini M; Mancarella M; Cassinerio E; Marcon A; Ambrogio AG; Motta I
Am J Hematol; 2017 Jun; 92(6):E119-E121. PubMed ID: 28321923
[No Abstract] [Full Text] [Related]
[Next] [New Search]
